LMWH Dosing for Cerebral Venous Thrombosis
For a 70 kg adult with cerebral venous thrombosis and normal renal function, use enoxaparin 1 mg/kg subcutaneously twice daily (70 mg twice daily) or enoxaparin 1.5 mg/kg once daily (105 mg once daily), with the twice-daily regimen preferred for this serious condition.
Preferred Dosing Regimen
Low-molecular-weight heparin is strongly preferred over unfractionated heparin for cerebral venous thrombosis 1. The evidence specifically supports:
- Enoxaparin 1 mg/kg subcutaneously every 12 hours (70 mg twice daily for a 70 kg patient)
- Alternative: Enoxaparin 1.5 mg/kg once daily (105 mg once daily for a 70 kg patient)
The twice-daily dosing is generally preferred for cerebral venous thrombosis given the severity of the condition, though once-daily dosing has been validated in general VTE 2.
Supporting Evidence
Multiple guidelines consistently recommend therapeutic-dose LMWH for acute VTE treatment 2, 3, 4. For cerebral venous thrombosis specifically:
- LMWH demonstrates superior outcomes compared to unfractionated heparin, with better functional independence at 6 months (OR 2.4) and fewer new intracranial hemorrhages (adjusted OR 0.19 in patients with baseline intracerebral lesions) 5
- A randomized trial showed significantly lower hospital mortality with LMWH versus UFH in CVT patients (0 deaths vs 6 deaths, p=0.01) 6
- Anticoagulation should be initiated immediately upon diagnosis, even in the presence of hemorrhagic venous infarcts 1, 7
Alternative LMWH Options
If enoxaparin is unavailable, alternative therapeutic dosing includes 2, 3, 4:
- Dalteparin 200 IU/kg once daily (14,000 IU daily for 70 kg)
- Dalteparin 100 IU/kg twice daily (7,000 IU twice daily for 70 kg)
- Tinzaparin 175 IU/kg once daily (12,250 IU daily for 70 kg)
Duration and Transition
- Continue LMWH for at least 5-7 days while overlapping with oral anticoagulation 2
- Transition to oral anticoagulation (warfarin with INR 2-3, or DOACs) for 3-12 months total duration 1, 8
- Recent evidence supports DOACs as acceptable alternatives to warfarin after the acute phase 8, 9
Critical Considerations
With normal renal function (CrCl >30 mL/min), no dose adjustment is needed 2. However, monitor for:
- Platelet counts every 2-3 days from day 4-14 to screen for heparin-induced thrombocytopenia, though risk is lower with LMWH than UFH 2
- Anti-Xa monitoring is NOT routinely indicated with normal renal function and standard body weight 10
- Clinical deterioration requiring consideration of decompressive surgery if large space-occupying venous infarcts develop 1, 7
Common Pitfalls to Avoid
- Do not withhold anticoagulation due to presence of hemorrhagic transformation—this is common in CVT and anticoagulation remains indicated 1, 7
- Do not use prophylactic doses—full therapeutic anticoagulation is required 1
- Do not delay treatment for additional testing—initiate immediately upon diagnosis 7, 8